Related Experiment Video
Updated: Jul 28, 2026
13:36
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Recombinant bacillus Calmette-Guérin as a potential vector for preventive HIV type 1 vaccines
L A Falk1, K L Goldenthal, J Esparza
1U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Rockville, Maryland 20852-1448, USA.
AIDS Research and Human Retroviruses
|February 5, 2000
Summary
Recombinant bacillus Calmette-Guérin (rBCG) shows promise as a vectored vaccine for Human Immunodeficiency Virus (HIV). Further research and development are prioritized to advance this potential HIV vaccine candidate toward clinical trials.
Area of Science:
- Immunology
- Vaccinology
- Microbiology
Background:
- The World Health Organization (WHO) and Joint United Nations Programme on HIV/AIDS (UNAIDS) convened expert groups to address Human Immunodeficiency Virus type 1 (HIV-1) vaccine development strategies.
- Investigational work by Japan's National Institute of Infectious Diseases (NIID) highlighted the potential of recombinant bacillus Calmette-Guérin (rBCG) as a vectored vaccine for HIV.
Framework:
- The feasibility of a BCG-vectored HIV vaccine was assessed, focusing on scientific data regarding the use of rBCG as a vector for preventive HIV vaccines.
- Discussions centered on the progress of this vaccine approach and related research areas.
Implementation:
- The working group reconvened to evaluate advancements and discuss necessary steps for moving candidate vaccines into Phase 1 clinical trials.
- Recommendations were formulated to facilitate the long-term development of rBCG-vectored HIV vaccines.
Implications:
- This research prioritizes the advancement of novel HIV vaccine candidates, specifically those utilizing rBCG as a vector.
- The findings aim to guide future research and development efforts toward successful clinical translation of BCG-vectored HIV vaccines.
